Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia

Percentage of Participants With Virologic Response at End of Treatment (EoT)

Virologic response is defined as HCV RNA level \<50 IU/mL.

Time frame: Up to EoT, maximum of 24 weeks

Number of Participants Meeting Premature Study Drug Discontinuation

Premature study drug discontinuation was defined as participants who prematurely discontinued study drug (ABBVIE REGIMEN or RBV) and who experienced no on-treatment virologic failure (defined as breakthrough \[at least 1 documented HCV RNA ˂50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment\] or failure to suppress \[each measured on-treatment HCV RNA value ≥50 IU/mL\]).

Time frame: Up to EoT, maximum of 24 weeks

Percentage of Participants Meeting Each and Any SVR12 Non-response Criteria

For a participant to be include in this analysis, the participant needed to meet each and any of the following SVR12 non-response categories: * On-treatment virologic failure (breakthrough \[defined as at least one documented HCV RNA \<50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment\] or failure to suppress \[each measured on-treatment HCV RNA value ≥50 IU/mL\]); * Relapse (defined as HCV RNA \<50 IU/mL at actual EoT followed by HCV RNA ≥50 IU/mL post-treatment for participants who completed treatment \[not more than 7 days shortened\]); * Premature study drug discontinuation with no on-treatment virologic failure; * Missing SVR12 data and/or none of the above criteria (including participants with missing SVR12 data). Abbreviations: EoT=end of treatment.

Time frame: During treatment and 12 weeks (i.e. at least 70 days) after the last dose of study drug (up to 24 weeks)

Percentage of Participants With Relapse

Relapse was defined as confirmed HCV RNA \<50 IU/mL at EoT or at the last on-treatment HCV RNA measurement followed by HCV RNA ≥50 IU/mL post-treatment in participants who were treated.

Time frame: 12 weeks (i.e. at least 70 days) after the last dose of study drug

Percentage of Participants With Relapse at EoT

Relapse was defined as confirmed HCV RNA \<50 IU/mL at EoT followed by HCV RNA ≥50 IU/mL post treatment in participants who completed treatment (actual duration of ABBVIE REGIMEN is not shortened more than 7 days) and had HCV RNA results available in the SVR12 window.

Time frame: 12 weeks (i.e. at least 70 days) after the last dose of study drug

Percentage of Participants With Viral Breakthrough

Viral breakthrough was defined as at least 1 documented HCV RNA \<50 IU/mL followed by HCV RNA ≥ 50 IU/mL during treatment.

Time frame: Up to EoT, maximum of 24 weeks

Percentage of Participants Meeting On-treatment Virologic Failure

On-treatment virologic failure was defined as breakthrough (at least 1 documented HCV RNA \<50 IU/mL followed by HCV RNA≥ 50 IU/mL during treatment) or failure to suppress (each measured on-treatment HCV RNA value ≥50 IU/mL).

Time frame: Up to EoT, maximum of 24 weeks

Percentage of Participants With Rapid Virologic Response at Week 4 (RVR4)

RVR4 was defined as HCV RNA \< 50 IU/mL at Week 4.

Time frame: Week 4

Percentage of Participants With Sustained Virologic Response at 24 Weeks (SVR24) After EoT

SVR24 was defined as HCV RNA \< 50 IU/mL 24 weeks after EoT. During the course of the study, standard of care was changing and it was no longer common practice to assess SVR24.

Time frame: 24 weeks after EoT (up to 24 weeks)